ASX Announcements, Company News 30 Apr 2026 Orthocell achieves first Remplir™ sales in US$75 million Canadian Market Orthocell has shared that it has completed the first commercial sales of Remplir™ in Canada, marking a key milestone in… Orthocell
ASX Announcements, Company News 20 Apr 2026 Orthocell reports continued growth and strong US momentum in March 2026 quarter Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued revenue growth, strong commercial… Orthocell
ASX Announcements, Company News 17 Apr 2026 First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network Orthocell has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs… Orthocell
ASX Announcements, Company News 16 Sep 2025 Global opportunity emerges as Remplir™ is used in nerve-sparing prostate cancer surgery Orthocell has identified a promising new application for its flagship Remplir™ nerve repair device - for use in nerve-sparing Robotic-Assisted… Orthocell
ASX Announcements, Company News 10 Jul 2025 First US Sales Revenue from Remplir™ Orthocell has today reached a critical milestone in the commercialisation of Remplir™ in the US$1.6 Billion US market, recording its… Orthocell
ASX Announcements, Company News 27 Jun 2025 First US Surgical Use of Remplir™ Orthocell recorded first use of Remplir™ in the US overnight, which is an important step in establishing surgical experience and… Orthocell
ASX Announcements, Company News Back view of young disabled black man in wheelchair spreading his arms, feeling happy and free on walk at city park. Full length of handicapped guy with backpack going on trip outdoors 19 Jun 2025 Breakthrough Study Confirms Remplir™ Superiority Over Standard US Nerve Repair Technique Orthocell has today announced interim results from a new study demonstrating that Remplir™ delivers superior nerve regeneration, earlier return to… Orthocell
ASX Announcements, Company News 12 May 2025 Orthocell Receives Regulatory Approval for Remplir™ in Hong Kong Orthocell has received regulatory approval from the Hong Kong Department of Health's Medical Device Division to commence sales of Remplir™… Orthocell
ASX Announcements, Company News 09 May 2025 Orthocell US Remplir™ Sales Rollout Gains Pace with 12 Distributors Now Appointed Covering 21 States Orthocell has appointed 12 US distributors for its nerve repair product Remplir™, well ahead of the expected target of 10… Orthocell
ASX Announcements, Company News 30 Apr 2025 Orthocell Secures Health Canada Approval for Remplir™ in US$75 million Canadian Market Orthocell has secured a Medical Device Licence from Health Canada for Remplir™, opening access to the US$75 million Canadian nerve… Orthocell
